

Rafael Santana-Davila

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/24508/publications.pdf>

Version: 2024-02-01

20
papers

1,649
citations

933447

10
h-index

888059

17
g-index

20
all docs

20
docs citations

20
times ranked

2191
citing authors

#	ARTICLE	IF	CITATIONS
1	Non-Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment. Mayo Clinic Proceedings, 2019, 94, 1623-1640.	3.0	1,153
2	A Phase II Trial of Pembrolizumab and Vorinostat in Recurrent Metastatic Head and Neck Squamous Cell Carcinomas and Salivary Gland Cancer. Clinical Cancer Research, 2020, 26, 837-845.	7.0	120
3	Cisplatin and Etoposide Versus Carboplatin and Paclitaxel With Concurrent Radiotherapy for Stage III Non-Small-Cell Lung Cancer: An Analysis of Veterans Health Administration Data. Journal of Clinical Oncology, 2015, 33, 567-574.	1.6	114
4	A Phase I Clinical Trial of AZD1775 in Combination with Neoadjuvant Weekly Docetaxel and Cisplatin before Definitive Therapy in Head and Neck Squamous Cell Carcinoma. Clinical Cancer Research, 2018, 24, 2740-2748.	7.0	76
5	Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study. Lancet Oncology, The, 2021, 22, 1740-1751.	10.7	46
6	Phase 1 Expansion Cohort of Ramucirumab Plus Pembrolizumab in Advanced Treatment-Naive NSCLC. Journal of Thoracic Oncology, 2021, 16, 289-298.	1.1	35
7	Harnessing the Immune System as a Therapeutic Tool in Virus-Associated Cancers. JAMA Oncology, 2017, 3, 106.	7.1	16
8	Ramucirumab (R) plus pembrolizumab (P) in treatment naive and previously treated advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: A multi-disease phase I study.. Journal of Clinical Oncology, 2017, 35, 4046-4046.	1.6	14
9	Phase II trial of eribulin mesylate in recurrent or metastatic salivary gland malignancies. Head and Neck, 2018, 40, 584-589.	2.0	13
10	A Pilot Study of Atezolizumab Plus Hypofractionated Image Guided Radiation Therapy for the Treatment of Advanced Non-Small Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2020, 108, 170-177.	0.8	13
11	Duration of Targeted Therapy in Patients With Advanced Non-small-cell Lung Cancer Identified by Circulating Tumor DNA Analysis. Clinical Lung Cancer, 2020, 21, 545-552.e1.	2.6	11
12	Performance status (<sc>PS</sc>) as a predictor of poor response to immune checkpoint inhibitors (<sc>ICI</sc>) in recurrent/metastatic head and neck cancer (<sc>RMHNSCC</sc>) patients. Cancer Medicine, 2022, 11, 4104-4111.	2.8	11
13	A phase I study of pazopanib in combination with escalating doses of 131I in patients with well-differentiated thyroid carcinoma borderline refractory to radioiodine. PLoS ONE, 2017, 12, e0178325.	2.5	10
14	Predictors of outcome with cetuximab and paclitaxel for head and neck squamous cell carcinoma. Laryngoscope, 2017, 127, 1583-1588.	2.0	8
15	The use of combination immunotherapies as front-line therapy for non-small-cell lung cancer. Future Oncology, 2018, 14, 191-194.	2.4	5
16	Immunotherapy for Head and Neck Cancer in the Era of Exponentially Increasing Health Care Expenditure. Oncologist, 2018, 23, 147-149.	3.7	2
17	A phase I clinical trial of AZD1775 in combination with neoadjuvant weekly cisplatin and docetaxel in borderline resectable head and neck squamous cell carcinoma (HNSCC).. Journal of Clinical Oncology, 2017, 35, 6034-6034.	1.6	2
18	A Phase II study of nab-Paclitaxel (nab-P) in patients with advanced non-small cell lung cancer with EGFR mutations after frontline tyrosine kinase inhibitor therapy. Cancer Treatment and Research Communications, 2021, 28, 100416.	1.7	0

#	ARTICLE	IF	CITATIONS
19	Prognostic significance of performance status in patients with head and neck squamous cell carcinomas (HNSCC) receiving immune checkpoint monoclonal antibodies (ICmAB) in a single institution.. Journal of Clinical Oncology, 2017, 35, e17506-e17506.	1.6	0
20	High End-of-Life Health Care Utilization in a Contemporary Cohort of Head and Neck Cancer Patients Treated with Immune Checkpoint Inhibitors. Journal of Palliative Medicine, 2021, , .	1.1	0